CF
IMUX icon

Cantor Fitzgerald’s Immunic IMUX Stock Holding History

Cantor Fitzgerald’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,300
Closed -$21.4K – 309
2024
Q3 		$21.4K Buy
+1,300
New +$18.5K ﹤0.01% 181

Other funds holding IMUX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $97.6B AUM 29.43% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Cantor Fitzgerald's IMUX Position: Q4 2024 in Review

Cantor Fitzgerald sold out of Immunic (IMUX) in Q4 2024, closing a stake of 1,300 shares — an estimated $21.4K sold.

Cantor Fitzgerald first reported a position in IMUX in Q3 2024 and held it in 1 quarter. The position peaked at $21.4K in Q3 2024. 65 funds tracked by Wall St. Rank hold IMUX as of Q4 2024.

  • Cantor Fitzgerald reported no remaining Immunic position as of Q4 2024 after selling out during the quarter.
  • Cantor Fitzgerald sold 1,300 Immunic shares in Q4 2024, an estimated $21.4K.
  • Cantor Fitzgerald first reported a position in Immunic in Q3 2024 and held it in 1 quarter.
  • Cantor Fitzgerald's Immunic position peaked at $21.4K in Q3 2024.
  • 65 funds tracked by Wall St. Rank held Immunic as of Q4 2024.

Based on Cantor Fitzgerald's 13F filing for Q4 2024, filed 14 Feb 2025.